SL Science Holding Ltd

SL Science Holding Ltd (Nasdaq: SLBT), formerly known as SL BIO Ltd., is a biomedical company headquartered in Taipei, Taiwan, specializing in the development of innovative cellular and gene therapies. The company focuses on advancing groundbreaking cell and gene therapies while expanding its portfolio in regenerative medicine and oncology. SL Science Holding Ltd is dedicated to redefining cell therapy through its proprietary GDT platform, which aims to transform cell therapy into a standardized, scalable, and reproducible global platform. Their research concentrates on investigational immune cell technologies currently in preclinical development, including proprietary Armed-T and gamma delta (γδ) T cells. These technologies are designed to enhance anti-cancer immune responses with improved safety, scalability, and accessibility across high-unmet-need indications such as blood, pancreatic, and brain cancers. In addition to immune cell technologies, SL Science Holding Ltd has developed a novel exosome portfolio formulated from non-human sources like plants and bovine milk. These exosome and plant-extract products are ISO-certified and dermatologically tested for skin and hair care, offering cell-free regenerative solutions that are commercially distributed across Asia. The company's vision is to contribute to the future of healthcare by advancing research-driven innovation in immune cell science and non-cellular biologics, with a focus on supporting the development of preclinical platforms for oncology and regenerative research applications. Sources: [1] https://www.listingtrack.io/company?symbol=SLBT&name=SL%20Science%20Holding%20Ltd [2] https://www.sahmcapital.com/news/content/sl-bio-closes-spac-merger-with-horizon-space-acquisition-ii-corp-set-to-begin-nasdaq-trading-as-slbt-on-june-15-2026-06-12 [3] https://www.slbtgroup.com/